Imaging in Renal Cell Carcinoma
Authors:
- Katherine M. KrajewskiKKKatherine M. Krajewski
- Angela A. GiardinoAGAngela A. Giardino
- Katherine ZukotynskiKZKatherine Zukotynski
- Annick D. Van Den AbbeeleAAAnnick D. Van Den Abbeele
- Ivan PedrosaIPIvan Pedrosa
- 1 August 2011
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 25 (4) , 687-715
Abstract
No abstract availableKeywords
This publication has 104 references indexed in Scilit:
- Targeted therapies in renal cell cancer: recent developments in imagingTargeted Oncology, 2010
- Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatmentTargeted Oncology, 2010
- Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced UltrasonographyClinical Cancer Research, 2010
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibBritish Journal of Cancer, 2010
- Does Arterial Spin-labeling MR Imaging–measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?Radiology, 2009
- FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoBritish Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant MelanomaClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000